Bone News and Research

RSS

More effective therapeutic exercises underutilized in treatment of chronic neck pain

Duke University and University of North Carolina (UNC) researchers report in the November issue of Arthritis Care & Research that narcotics and diagnostic testing are overused in treating chronic neck pain. Their findings indicate clinicians may overlook more effective treatments for neck pain, such as therapeutic exercise. According to reviews cited in the study, evidence to support the effectiveness of therapeutic exercise in treating chronic neck pain is good, yet only 53% of subjects were prescribed such exercise.

28 Oct 2010

TU/e researchers mimic process of bone formation in laboratory

Researchers at Eindhoven University of Technology (TU/e) have for the first time succeeded in mimicking the process of bone formation in the laboratory, and in visualizing the process in great detail. The results will be published in the December edition of the scientific journal Nature Materials.

28 Oct 2010

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

New guideline for using ESAs drugs in cancer patients

An updated joint guideline by the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO) advises physicians about the appropriate use of erythropoiesis-stimulating agents (ESAs), a class of drugs that stimulate the bone marrow to produce more red blood cells, to treat cancer patients with chemotherapy-induced anemia.

27 Oct 2010

Rockwell receives SFP patent for GMP formulation

Rockwell Medical a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received notice from the U.S. Patent and Trademark Office for patent issuance on its proprietary GMP formulation for Soluble Ferric Pyrophosphate (SFP), the Company's lead-drug candidate for treating iron deficiency anemia in ESRD patients.

27 Oct 2010

Aastrom Biosciences and ATEK Medical enter new strategic partnership

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, and ATEK Medical, a leading medical device manufacturer, today announced the formation of a new strategic partnership in which ATEK Medical will supply key components and technology for use in Aastrom's proprietary cell manufacturing process.

26 Oct 2010

TransPharma announces positive results of ViaDerm-hPTH Phase 1 trial for osteoporosis treatment

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today successful results of a 4 week Phase 1 trial of its new self-applied ViaDerm-hPTH(1-34) for the treatment of osteoporosis.

26 Oct 2010

Racial disparities among children with frequent ear infections can influence access to health care resources

Ear infections are one of the most common health problems for children, with most kids experiencing at least one by their third birthday. Annual costs in the United States alone are in the billions of dollars.

26 Oct 2010

Lumiphore signs global cooperation with Algeta to integrate Lumi4 complexes

Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA a leading company specializing in innovative radiopharmaceutical therapies to treat cancer patients. The agreement enables the integration of Lumiphore's Lumi4 complexes into the targeted radiotherapeutics and companion diagnostics from Algeta.

From Thermo Fisher Scientific Inc. 26 Oct 2010

Researchers identify signaling pathway that promotes metastasis of pediatric bone cancer

Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer. Their research showed that the Notch pathway and Hes1 gene play a key role in promoting the metastasis of osteosarcoma, the most common form of bone cancer in children.

26 Oct 2010

Aspirin reduces risk of death from prostate cancer

Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.

26 Oct 2010

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.

26 Oct 2010

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen reported revenue unchanged for the third quarter of 2010 at $3,816 million versus $3,812 million for the third quarter of 2009.

26 Oct 2010

Daily dose of whole body vibration reduces bone density loss

A daily dose of whole body vibration may help reduce the usual bone density loss that occurs with age, Medical College of Georgia researchers report.

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Barriers for female heart patients entering cardiac rehab

Cardiac rehabilitation is considered the pillar of preventing a second cardiac event yet those who stand to benefit the most - women and the elderly − are often missing out, Dr. Billie Jean Martin told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.

25 Oct 2010

CARTaGENE database meets 20k participant milestone

This week, the last questionnaire was filled out and the final vial of blood was drawn, closing CARTaGENE's first ambitious goal of collecting samples and data from 20 000 Quebecers.

25 Oct 2010

FlexBone shows potential replacement for current bone transplantations

With a failure rate as high as 50 percent, bone tissue grafts pose a significant obstacle to orthopedic surgeons attempting to repair complex fractures or large areas of bone loss, such as those often caused by trauma and cancer. Current synthetic substitutes rarely possess the bone-like properties needed for successful grafting and are often difficult for surgeons to manipulate in the operating room. In response to these challenges, researchers at UMass Medical School have developed an easy-to-produce, inexpensive, synthetic bone material called FlexBone.

25 Oct 2010

$Precautions needed against cold-related frostbite, ankle sprains and fractures$

Precautions needed against cold-related frostbite, ankle sprains and fractures

With cold weather on the horizon, podiatrists at Temple University's School of Podiatric Medicine warn that people of all ages need to take precautions to protect their feet from cold-related injuries like frostbite, ankle sprains and fractures.

25 Oct 2010

NIH awards $3.9M for Fanconi anemia research

The National Institutes of Health has awarded a three-year, $3.9 million grant to Children's Hospital Boston researchers and their colleagues to develop a therapy to treat Fanconi anemia, a fatal genetic blood disease.

25 Oct 2010